In summary, CCL2 and HGF co-treatment enhanced proliferation, survival, and invasion in DCIS.com and HCC1937 breast cancer cells over CCL2 or HGF alone, with some differences in responsiveness to CCL2 and HGF between the cell lines. Here, CCL2 is linked to ductal breast carcinoma in situ.